ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Takeda’s Alunbrig beats Pfizer’s Xalkori on PFS in ALK positive NSCLC
July 27, 2018Takeda’s Alunbrig has beaten Pfizer's Xalkori on progression-free survival (PFS) in a Phase III trial testing its efficacy as a front-line treatment for ALK-positive lung cancer. -
Crizotinib-radiation therapy combination may help preserve hearing in NF2
February 07, 2018Adding the targeted cancer therapy drug crizotinib to radiation therapy for tumours associated with the genetic disorder neurofibromatosis 2 may reduce the hearing damage that can be exacerbated by radiotherapy…
Pharma Sources Insight January 2025
